NUVLFDA PDUFA
Potential regulatory action window
Nuvalent | Zidesamtinib | ROS1-positive NSCLC
Catalyst details
Manual FDA catalyst entered from company guidance and regulatory filings.
Phase
Registration
Expected date
2026-11-20
Expected period
Q4 2026
Source type
manual
quarterupcoming
Source URLNotes
This record is structured for public-source tracking and manual analyst override. The database stores date confidence separately from exact dates so quarter, half-year, and estimated guidance can be handled without inventing precision.
Open company detailHistory of changes
No sample changes for this catalyst.